Immunome Inc. (IMNM): CEO Uses Capital Increase for a Private Investment of $1.16 Million
Reading Time: 2 minutes
Immunome Inc. (IMNM) specializes in the development of targeted therapies to improve treatment outcomes for cancer patients. The company is advancing an innovative portfolio of therapeutics, leveraging a leadership team that has played crucial roles in the development and commercialization of cutting-edge, targeted cancer therapies, including antibody-drug conjugates (ADCs). In addition to a portfolio of ADCs in the discovery phase, the pipeline also includes AL102, a gamma-secretase inhibitor currently in a Phase 3 study for the treatment of desmoid...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
